該当箇所へ

Meet the Genedata Biologics Community

Virtual Genedata Biologics Partner Symposium: April 13–15, 2021
Genedata Biologics Partner Symposium

The 7th Annual Genedata Biologics Partner Symposium is a unique interdisciplinary event at the interface between biopharma R&D and IT. Presentations and discussions will focus on innovative applications and new industry requirements, such as novel molecular formats and therapeutic modalities (e.g., multispecifics, CAR-Ts, TCRs, AAVs) and increasing automation and standardization in biopharmaceutical R&D.

Leading biopharma companies will show how they have set up, operate, and use Genedata to transform their biotherapeutics research & development and how this results in increased efficiency and throughput.

Previous Genedata symposia have included customer presentations from AbbVie, Bayer, Boehringer Ingelheim, Celgene, EMD Serono, Genzyme, GSK, Janssen, Merck, Morphosys, Pfizer, Sanofi, Sartorius, Takeda, UCB, and many others.

Due to the ongoing travel restrictions, the Partner Symposium will be held in a fully virtual format in 2021.  This invitation-only event is limited to Genedata customers and is free to attend. 



See the Agenda in Your Preferred Time Zone

Agenda

Tuesday, April 13, 2021
Pre-Symposium Poster Session (Session repeated at end of day)
Opening Remarks 
Othmar Pfannes, CEO, Genedata, Basel, Switzerland
Jana Hersch, Scientific Consultant, Genedata, Basel, Switzerland
Keynote – Pfizer’s New Gene Therapy Workflows – AAVs and Beyond
Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
Clone Batch Customizations in Genedata Biologics enabling New Automation Platforms at GSK 
Daniel Badcock, Scientific Leader, High Throughput Antibody Expression and Purification, GSK Medicines Research Centre, Stevenage, UK
Janssen's High-Throughput Biopharma R&D in the Digital Age
John Boles, Business Technology Leader, Janssen, Spring House, PA, USA 
Siva Sakkiahpandy, Project Manager, Janssen, Spring House, PA, USA 
Kim Munsell, Senior Computer System Validation and Compliance Manager, Janssen, Spring House, PA, USA 
Virtual Coffee Break @ the Genedata Cafe
BI’s Data Review Center – Optimizing Checks and Balances for Biophysical Data Entry into Genedata Biologics
Samuel Cheng, IS Lead Business Consultant, IT RDM Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
Tadas Panavas, Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
Genedata Biologics @ Novartis – Pushing the Limits
Björn Hüber, Team Leader Data Management, Novartis - NIBR Biologics Center, Basel, Switzerland
Desmond Fox, NX Business Analyst, Novartis - NIBR Biologics Center, Basel, Switzerland
Biologics Update & Roadmap: Automation, Cell and Gene Therapies, and Other Innovations 
Guido Cappuccilli, Product Manager, Genedata, Basel, Switzerland 
Closing Remarks
Post-Symposium Poster Session (Repeat of Pre-Symposium Session)
Wednesday, April 14, 2021
Pre-Symposium Demo Session (Session repeated at end of day)
Opening Remarks 
Jessy Sheng, Scientific Consultant, Genedata, San Francisco, CA, USA 
Keynote – Janssen's Biotherapeutic Workflows – Multispecifics, CAR-Ts and More
Patrick Doonan, Principal Scientist, Janssen, Spring House, PA, USA
Ninkka Tamot, Scientist, Janssen, Spring House, PA, USA
TCER® Development at Immatics and Deployment of Genedata
Felix Unverdorben, Associate Director Immunology, Immatics Biotechnologies, Tübingen, Germany
Building onto Genedata Biologics – Integration Backbone for Sanofi’s R&D IT Infrastructure
Jay Randazzo, Digital Service Owner – Large Molecule Research, Sanofi, Cambridge, MA, USA
Joachim Meyer, IT Solution Expert Biologics, Sanofi, Frankfurt am Main, Germany
Virtual Coffee Break @ the Genedata Cafe
Panel Discussion – Cell & Gene Therapy Trends, Challenges & Bottlenecks
Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
Ninkka Tamot, Scientist, Janssen, Spring House, PA, USA
Hugo de Wit, Head of Advanced Therapies, Sartorius, Ulm, Germany
Streamlining Cell Line Development Processes at Sartorius – Increasing Productivity by a Factor of Three
Hugo de Wit, Head of Advanced Therapies, Sartorius, Ulm, Germany
Genedata Biologics & Bioprocess Deployment at Octapharma: From Lead Discovery to Formulation
Christoph Schanzenbächer, Scientist, Recombinant Research and Development, Octapharma Biopharmaceuticals GmbH, Heidelberg, Germany
Genedata Bioprocess Update & Roadmap: CLD, USP, DSP, Formulation and Analytical Development
Yang-Chieh Chou, Product Manager, Genedata, Basel, Switzerland
Closing Remarks
Post-Symposium Demo Session (Repeat of Pre-Symposium Session)
Thursday, April 15, 2021
Pre-Symposium Virtual Coffee Break @ the Genedata Cafe
Opening Remarks
Adrienne Craig-Kennard, Head of Biologics Sales, US, Genedata, San Francisco, CA, USA
Connecting Biotherapeutics Across Two Heritage Companies: Our Journey to Extend Genedata Use at BMS
Lore Florin, Director Antibody Generation, Bristol Myers Squibb, Redwood City, CA, USA
Integrating Biologics with Merck’s R&D Data Systems 
Sameh Eid, Principal Scientist, Research Informatics, Merck Healthcare KGaA, Darmstadt, Germany
Erin Williams, Associate Lab Head / Scientific Manager, Quality Control, EMD Serono, Billerica, MA, USA
Panel Discussion – Digitalization in Biopharma R&D: Where are we Now and Where are we Going?
Yuan Lin, Biologics Business Partner, Pfizer, Cambridge, MA, USA
Przemek Stasica, Biopharm Discovery Data Designer, GSK, Medicines Research Centre, Stevenage, MA, USA
Uwe Wittenberg, Director Research Informatics, Merck Healthcare, Darmstadt, Germany
Lore Florin, Director Antibody Generation, Bristol Myers Squibb, Redwood City, CA, USA
Tristan Magnay, Digital Biologics Platform Site Lead, US, Sanofi, Framingham, MA, USA
Karsten Thierbach, Group Manager R&D Purification and Analytics III, Octapharma, Heidelberg, Germany
Markus Sanna, Manager Digital Data Excellence and IT Services, Sartorius Stedim Cellca GmbH, Ulm, Germany
Virtual Coffee Break @ the Genedata Cafe
Using Genedata Biologics to Improve Biotherapeutic Decisions at Pfizer
Joseph DeBartolo, Senior Principal Scientist, BioMedicine Design, Pfizer, Cambridge, MA, USA
Sanofi's PEPP System and Genedata Biologics – High-Throughput Mid-Scale Production of Multi-Format Proteins
Tristan Magnay, Digital Biologics Platform Site Lead, US, Sanofi, Framingham, MA, USA
Genedata Architecture 2021 Initiative
Sebastian Schlicker, Head of Operations, Genedata, Basel, Switzerland
Closing Remarks
Post-Symposium Virtual Coffee Break @ the Genedata Cafe
End of Symposium